Subtype
High Grade Astrocytic Tumor
CI-CAN-00005503Explore in graph →
495 active trials2 approved drugs51 evidence items
- NCIt
- C102897
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005503Explore in graph →
Clinical trials
1,778 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (282)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01434602 | Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas | completed | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2022 | clinicaltrials |
| NCT05399524 | Functional and Ultrasound Guided Resection of Glioblastoma(FUTURE-GB) | unknown | N/A | 357 | University of OxfordOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT02709616 |
| Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)(PERCELLVAC) |
| completed |
| Phase 1 |
| 10 |
| Guangdong 999 Brain HospitalOTHER |
| 1 |
| May 27, 2022 |
| clinicaltrials |
| NCT02808364 | Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2)(PerCellVac2) | completed | Phase 1 | 10 | Guangdong 999 Brain HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT00045968 | Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer(GBM) | unknown | Phase 3 | 348 | Northwest BiotherapeuticsINDUSTRY | 4 | May 18, 2022 | clinicaltrials |
| NCT00669669 | O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas | terminated | Phase 1 / Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT02871843 | RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas(G-FORCE-1) | completed | Phase 1 | 19 | EpicentRx, Inc.INDUSTRY | 1 | May 16, 2022 | clinicaltrials |
| NCT03216499 | HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma(PT2385) | completed | Phase 2 | 24 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT04708171 | The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections(PROGRAM) | recruiting | — | 453 | Erasmus Medical CenterOTHER | 5 | May 6, 2022 | clinicaltrials |
| NCT03641326 | Sunitinib in Sarcomas of the Central Nervous System | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Apr 19, 2022 | clinicaltrials |
| NCT04219475 | Predicting Response Patterns to Treatment in Glioblastoma (GBM) Patients(PROPHETIC) | suspended | — | 1,000 | OncoHost Ltd.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT05333588 | The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme. | unknown | Early Phase 1 | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT02794883 | Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma | completed | Phase 2 | 36 | Northwestern UniversityOTHER | 1 | Apr 18, 2022 | clinicaltrials |
| NCT03390569 | Exercise in Patients With Glioblastoma | completed | N/A | 54 | University Health Network, TorontoOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT01004874 | Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma | completed | Phase 2 | 80 | Duke UniversityOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT02750891 | A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas | completed | Phase 1 / Phase 2 | 18 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT02843230 | Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI | completed | — | 30 | Massachusetts General HospitalOTHER | 1 | Apr 8, 2022 | clinicaltrials |
| NCT01904123 | STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain | completed | Phase 1 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT02359097 | Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma | completed | N/A | 29 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 17, 2022 | clinicaltrials |
| NCT04065087 | Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Genexine, Inc.INDUSTRY | 1 | Mar 17, 2022 | clinicaltrials |
| NCT04289155 | Individual Patient Compassionate Use of GX-I7 | no longer available | — | — | Genexine, Inc.INDUSTRY | 1 | Mar 17, 2022 | clinicaltrials |
| NCT04516733 | Precoce Medical Care by the Mobil Support for Patients With Glioblastoma(GLIOSUPPORT) | completed | N/A | 35 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Mar 14, 2022 | clinicaltrials |
| NCT02270034 | Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma | completed | Phase 1 | 38 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT01925573 | Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344) | terminated | N/A | 7 | University of Maryland, BaltimoreOTHER | 1 | Feb 3, 2022 | clinicaltrials |
| NCT02796261 | Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients(STELLAR) | unknown | Phase 3 | 343 | Orbus Therapeutics, Inc.INDUSTRY | 8 | Jan 21, 2022 | clinicaltrials |
| NCT05201326 | Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma | unknown | Phase 1 | 20 | Ruijin HospitalOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT03341806 | Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma | completed | Phase 1 | 13 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT01222754 | Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Jan 3, 2022 | clinicaltrials |
| NCT03990285 | [18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin )(Axumin) | completed | Phase 1 | 30 | Ali NabavizadehOTHER | 1 | Dec 22, 2021 | clinicaltrials |
| NCT03400917 | Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma | unknown | Phase 2 | 55 | Aivita Biomedical, Inc.INDUSTRY | 1 | Dec 16, 2021 | clinicaltrials |
| NCT01331616 | Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab | withdrawn | Early Phase 1 | 0 | West Penn Allegheny Health SystemOTHER | 0 | Dec 9, 2021 | clinicaltrials |
| NCT00805961 | RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM | completed | Phase 2 | 68 | SCRI Development Innovations, LLCOTHER | 1 | Dec 8, 2021 | clinicaltrials |
| NCT04888611 | Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma | unknown | Phase 2 | 40 | Huashan HospitalOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT01856933 | BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) | completed | Phase 2 | 6 | Heinrich Elinzano, MDOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05131711 | Combination of Stereotactic Radiosurgery and Enhanced Immunotherapy for Recurrent Glioblastomas(inSituVac2)(CSREIG)(CSREIG) | unknown | Phase 1 / Phase 2 | 60 | Beijing Tiantan HospitalOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05131763 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | unknown | Phase 1 | 3 | Fudan UniversityOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT02010606 | Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma | completed | Phase 1 | 39 | Cedars-Sinai Medical CenterOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT05108012 | Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients | unknown | Phase 1 | 5 | Royan InstituteOTHER_GOV | 1 | Nov 22, 2021 | clinicaltrials |
| NCT03291990 | 5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme | completed | Early Phase 1 | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 19, 2021 | clinicaltrials |
| NCT03374943 | A Trial of KB004 in Patients With Glioblastoma | completed | Phase 1 | 12 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT01189266 | Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma | completed | Phase 1 / Phase 2 | 79 | National Cancer Institute (NCI)NIH | 3 | Oct 28, 2021 | clinicaltrials |
| NCT03422094 | Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma | terminated | Phase 1 | 3 | Washington University School of MedicineOTHER | 1 | Oct 27, 2021 | clinicaltrials |
| NCT03235934 | Glycemic Impact on Glioblastoma Outcomes | withdrawn | — | 0 | University Health Network, TorontoOTHER | 1 | Oct 25, 2021 | clinicaltrials |
| NCT02379572 | Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas | completed | N/A | 315 | University Hospital TuebingenOTHER | 1 | Oct 22, 2021 | clinicaltrials |
| NCT02015819 | Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas | completed | Phase 1 | 16 | City of Hope Medical CenterOTHER | 1 | Oct 20, 2021 | clinicaltrials |
| NCT01587144 | Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM) | terminated | Phase 2 | 18 | Spectrum Pharmaceuticals, IncINDUSTRY | 2 | Oct 19, 2021 | clinicaltrials |
| NCT00112502 | Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme | completed | Phase 2 | 178 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 18, 2021 | clinicaltrials |
| NCT01353625 | Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. | completed | Phase 1 | 118 | CelgeneINDUSTRY | 4 | Oct 5, 2021 | clinicaltrials |
| NCT02770378 | A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 10 | University of UlmOTHER | 1 | Oct 5, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Jun 1, 2022source: clinicaltrials